Increased battery longevity
The Micra™ AV2 and Micra™ VR2 have projected median longevities of nearly 16–17 years, meaning more than 80% of patients will only need one Micra™ device for life.2
These innovations required zero change to the device size.
Smarter AV synchrony
Micra™ AV2 automatically customizes AV synchrony settings for each patient, reducing the need for manual programming by more than 50% compared to Micra™ AV.2
The smarter algorithms also improve automatic AV synchrony at faster heart rates between 80–100 bpm,2 and the upper tracking rate limit is now 135 bpm.
Enhanced delivery system
The updated delivery system now has a rounded catheter tip with more surface area to decrease tip pressure during device implant.3
Micra™ AV2 and Micra™ VR2 devices are implanted with the same streamlined procedure that has been utilized by nearly 10,000 trained Micra™ physicians worldwide.5
Engineering meaningful innovation together
Micra™ AV2 and Micra™ VR2 provide an unmatched leadless pacing experience for bradycardia patients.
With improved battery longevity and smarter algorithms, most patients will only need one device for life.2
The 105 cm long delivery system has a handle that controls deflection and deployment of the Micra™ pacing capsule. There are five key components:
- Device deployment button
- Curve deflection button
- Tether lock button
- Tether pin
- Flush port
Introducer sheath
The Micra™ introducer sheath enables smooth vessel navigation with a lubricious hydrophilic coating and silicone oil-coated dilator tip. It has a 23 Fr inner diameter and 27 Fr outer diameter. There are three key components:
- Extended distal taper
- 56 cm (22 in) working length
- Side port with three-way stopcock
Real-world clinical evidence
Micra AV AccelAV study
Micra™ AV is an effective therapy for patients with AV block6
85.4% Sustained resting AV synchrony and stable through 3-months follow-up.
82.6% Improved ambulatory AV synchrony with optimized programming.
No upgrades through three months with no major complications due to pacemaker syndrome.
Micra AV CED study
30-day and 2-year results7,8
Administrative claims-based study of Medicare beneficiaries implanted with Micra AV (compared with a contemporaneous cohort of transvenous dual chamber pacemakers, TV-DC).
- 47% reduction in reinterventions (2-year)8
Micra AV PAR study9
1-year results (interim analysis)
Prospective, nonrandomized, real-world registry of Micra AV patients with adjudication of system and procedure-related events by an independent clinical events committee (compared with historical comparator cohort for transvenous dual chamber pacemakers, TV-DC).
Micra VR CED study10
3-year results
Administrative claims-based study of Medicare beneficiaries implanted with Micra VR (comparing with a contemporaneous cohort for transvenous single chamber pacemakers, TV-VVI).
Micra VR PAR study11
5-year results
Administrative claims-based study of Medicare beneficiaries implanted with Micra VR (comparing with a historical cohort for transvenous single chamber pacemakers, TV-VVI).
Models specifications
| Parameter |
Micra AV2 |
Micra VR2 |
|---|---|---|
| Pacing mode |
VVI, VVIR, VOO, OVO, VDD, VDI, ODO, OFF |
VVI, VVIR, VOO, OVO, OFF |
| Mass |
1.75 g |
1.75 g |
| Volume |
0.8 cc |
0.8 cc |
| Electrode spacing |
18 mm |
18 mm |
| Battery longevity |
15.6 years1 |
16.7 years1 |
| Accelerometer-based mechanical atrial sensing |
Yes |
N/A |
| Accelerometer-based rate response |
Yes |
Yes |
| MRI SureScan™ |
≤ 3T |
≤ 3T |
| CareLink™ remote monitoring |
Yes |
Yes |
Micra™ patient testimonials
Related pages
Request more information
Educational resources on Medtronic Academy
Access interactive courses, videos, and educational resources to extend your knowledge on Micra™.
†Rates adjusted for differences in patient baseline characteristics.
*CMS suppression requirement for values <11.
References
1
Nippoldt D, Whiting J. Micra Transcatheter Pacing System Device Volume Characterization Comparison. November 2014. Medtronic data on file.
2
Sheldon T, et al. Device Longevity and AV Synchrony Algorithm Modeling of a Leadless Pacemaker Family: A Virtual Patient Analysis. January 2023. Medtronic data on file.
3
Roberts PR et al, Preclinical cardiac perforation reduction in leadless pacing: An update to the Micra leadless pacemaker delivery system. Pacing Clin Electrophysiol. 2023 Sep;46(9):1085-1091.
4
Leick A. “Largest Reach” supporting data. September 2023. Medtronic Data on file.
5
Susumu A. 10,000 Micra trained physicians. February 2023. Medtronic data on file.
6
Chinitz LA, El-Chami MF, Sagi V, et al. Ambulatory atrioventricular synchronous pacing over time using a leadless ventricular pacemaker: Primary results from the AccelAV study. Heart Rhythm. January 2023;20(1):46–54.
7
Crossley, et al. Outcomes of Patients Implanted with an Atrioventricular Synchronous Leadless Ventricular Pacemaker in the Medicare Population. Heart Rhythm. September 2023. Heart Rhythm 2024;21:66–73
8
El-Chami et al. Two-year outcomes of Micra AV leadless pacemakers in the Micra AV CED study. Heart Rhtyhm, Volume 21, issue 5, supplement S356, MAY 2024 PO-03-037
9
Garweg, et al. A Leadless Ventricular Pacemaker Providing Atrioventricular Synchronous Pacing in the Real-World Setting: 12-Month Results from the Micra AV Post-Approval Registry. Heart Rhythm. June 2024
10
Crossley GH, Piccini JP, Longacre C, et al. Leadless versus transvenous single-chamber ventricular pacemakers: 3 year follow-up of the Micra CED study. J Cardiovasc Electrophysiol. April 2023;34(4):1015–1023.
11
El-Chami M, et al. Leadless pacemaker in 5-year follow-up: The Micra transcatheter pacing system post-approval registry. European Heart Journal (2024) 45, 1241–1251
